Clinical Trials Directory

We are doing this study to find out if an experimental drug called lasofoxifene (the study drug) is a safe and effective option for breast cancer. We want to see if the study drug combined with another drug called abemaciclib has better results than treatment with abemaciclib plus fulvestrant.

We are doing this study to learn more about how different factors in pregnancy lead to healthy babies. Specifically, whether factors related to father's health affect the placenta and baby, what part of placental and fetal genes are related to placenta health and baby growth, and to find out the best time to deliver when the mother has gestational diabetes.

If you can join, you will be placed in Part A or Part B based on when you start. In Part A, you will get one of three study medicines: SPY001, SPY002, or SPY003. In Part B, you will get one of these medicines, a mix of two medicines, or a placebo, which does nothing. The study will last about 97 weeks, and you will have around 20 visits or phone calls. During these, doctors will do tests like blood draws, endoscopy with biopsy, heart checks, and x-rays.

We are doing this study to find out if the Nectero EAST System® (the study procedure) is a safe and effective option for treating abdominal aortic aneurysms that are small to medium in size.

If you participate, you will be asked to provide a blood draw of about 5.4 mL, or 1/3 tablespoon, of blood. If you are one of the first 20 subjects, you may have the chance to participate in one additional blood draw.

This study has three parts, called Sub-Studies. In Sub-Study 1, people receive a medicine called duvakitug. In Sub-Study 2, people are placed by chance into one of three groups and may get duvakitug, a placebo with no medicine, or both depending on the group. In Sub-Study 3, people are placed by chance into one of two groups to get different doses of duvakitug. The whole study lasts about thirty-five weeks and includes fifteen clinic visits. During these visits, people will have tests such as heart checks, blood tests, endoscopy, biopsies, and questionnaires. Depending on when a person joins, they will be placed in Sub-Study 1 or Sub-Study 2. In both of these, they will take the study drug every two weeks for twelve weeks. After finishing one of these parts, they may be asked to join Sub-Study 3 for another twelve weeks of treatment, or they may be asked to join a different study called STARSCAPE 2.

We are doing this study to find out if an experimental drug called Zorevunersen (the study drug) can effectively reduce the frequency of major motor seizures for children who have Dravet syndrome.

People in the study will be split into two groups. One group will take a medicine called IDRX-42 every day as a white tablet. The other group will take a medicine called sunitinib in a capsule for 4 weeks, then stop for 2 weeks, and keep repeating that schedule. Both medicines are taken by mouth with a glass of water. Before starting, each person will have tests to make sure it is safe for them to join the study.